Geode Capital Management
MDGL icon

Geode Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Geode Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$239M Buy
455,870
+4,127
+0.9% +$1.97M 0.01% 668
2025
Q4 		$263M Buy
451,743
+5,510
+1% +$2.81M 0.02% 625
2025
Q3 		$205M Buy
446,233
+31,841
+8% +$11.9M 0.01% 689
2025
Q2 		$125M Sell
414,392
-6,483
-2% -$1.93M 0.01% 885
2025
Q1 		$139M Buy
420,875
+10,297
+3% +$3.38M 0.01% 784
2024
Q4 		$127M Buy
410,578
+4,923
+1% +$1.38M 0.01% 858
2024
Q3 		$86.1M Buy
405,655
+5,801
+1% +$1.48M 0.01% 1084
2024
Q2 		$112M Buy
399,854
+52,997
+15% +$12.6M 0.01% 860
2024
Q1 		$92.6M Buy
346,857
+10,602
+3% +$2.5M 0.01% 962
2023
Q4 		$77.8M Buy
336,255
+39,817
+13% +$6.97M 0.01% 1026
2023
Q3 		$43.3M Buy
296,438
+25,119
+9% +$4.73M 0.01% 1323
2023
Q2 		$62.7M Buy
271,319
+23,262
+9% +$6.3M 0.01% 1084
2023
Q1 		$60.1M Buy
248,057
+11,472
+5% +$3.13M 0.01% 1059
2022
Q4 		$68.7M Buy
236,585
+6,799
+3% +$665K 0.01% 939
2022
Q3 		$14.9M Buy
229,786
+4,984
+2% +$346K ﹤0.01% 1960
2022
Q2 		$16.1M Buy
224,802
+6,814
+3% +$501K ﹤0.01% 1915
2022
Q1 		$21.4M Sell
217,988
-2,030
-0.9% -$171K ﹤0.01% 1858
2021
Q4 		$18.6M Buy
220,018
+17,643
+9% +$1.45M ﹤0.01% 2005
2021
Q3 		$16.1M Buy
202,375
+4,271
+2% +$369K ﹤0.01% 2106
2021
Q2 		$19.3M Buy
198,104
+43,308
+28% +$5.13M ﹤0.01% 1988
2021
Q1 		$18.1M Buy
154,796
+12,790
+9% +$1.49M ﹤0.01% 1949
2020
Q4 		$15.8M Buy
142,006
+3,980
+3% +$486K ﹤0.01% 1869
2020
Q3 		$16.4M Sell
138,026
-764
-0.6% -$83K ﹤0.01% 1667
2020
Q2 		$15.7M Sell
138,790
-130
-0.1% -$12.8K ﹤0.01% 1662
2020
Q1 		$9.27M Buy
138,920
+14,987
+12% +$1.25M ﹤0.01% 1770
2019
Q4 		$11.3M Buy
123,933
+12,032
+11% +$1.17M ﹤0.01% 1930
2019
Q3 		$9.65M Buy
111,901
+2,433
+2% +$228K ﹤0.01% 1960
2019
Q2 		$11.5M Buy
109,468
+9,895
+10% +$1.06M ﹤0.01% 1851
2019
Q1 		$12.5M Buy
99,573
+9,057
+10% +$1.13M ﹤0.01% 1746
2018
Q4 		$10.2M Buy
90,516
+4,536
+5% +$702K ﹤0.01% 1776
2018
Q3 		$18.4M Buy
85,980
+5,964
+7% +$1.5M 0.01% 1472
2018
Q2 		$22.4M Buy
80,016
+28,514
+55% +$5.01M 0.01% 1272
2018
Q1 		$6.01M Sell
51,502
-2,797
-5% -$345K ﹤0.01% 2122
2017
Q4 		$4.98M Buy
54,299
+18,319
+51% +$1.05M ﹤0.01% 2218
2017
Q3 		$1.62M Buy
35,980
+3,740
+12% +$70K ﹤0.01% 2861
2017
Q2 		$524K Buy
32,240
+6,419
+25% +$100K ﹤0.01% 3340
2017
Q1 		$397K Buy
25,821
+216
+0.8% +$3.4K ﹤0.01% 3393
2016
Q4 		$381K Buy
25,605
+7,288
+40% +$117K ﹤0.01% 3370
2016
Q3 		$232K Buy
18,317
+9
+0% +$87 ﹤0.01% 3544
2016
Q2 		$166K Sell
18,308
-2,212
-11% -$26.5K ﹤0.01% 3653
2016
Q1 		$172 Sell
20,520
-11
-0.1% -$92 ﹤0.01% 3679
2015
Q4 		$252K Buy
20,531
+22
+0.1% +$604 ﹤0.01% 3593
2015
Q3 		$1.25M Buy
20,509
+1,440
+8% +$104K ﹤0.01% 2744
2015
Q2 		$1.49M Buy
19,069
+4,522
+31% +$379K ﹤0.01% 2675
2015
Q1 		$987K Buy
14,547
+2,062
+17% +$177K ﹤0.01% 2890
2014
Q4 		$1.16M Buy
12,485
+33
+0.3% +$3.41K ﹤0.01% 2755
2014
Q3 		$1.31M Buy
12,452
+1,319
+12% +$183K ﹤0.01% 2624
2014
Q2 		$1.59M Buy
11,133
+769
+7% +$112K ﹤0.01% 2522
2014
Q1 		$1.56M Buy
10,364
+2,741
+36% +$540K ﹤0.01% 2492
2013
Q4 		$1.4M Buy
7,623
+1,762
+30% +$323K ﹤0.01% 2515
2013
Q3 		$1.29M Buy
5,861
+621
+12% +$132K ﹤0.01% 2453
2013
Q2 		$915K Buy
+5,240
New +$1.37M ﹤0.01% 2512

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management's MDGL Position: Q1 2026 in Review

Geode Capital Management increased its Madrigal Pharmaceuticals (MDGL) stake by 0.91% in Q1 2026, buying an estimated $1.97M and bringing the position to 455,870 shares worth $239M. The position accounts for 0.01% of the portfolio, ranked #668.

Geode Capital Management first reported a position in MDGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $263M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Geode Capital Management held 455,870 shares of Madrigal Pharmaceuticals worth $239M as of Q1 2026.
  • Geode Capital Management bought 4,127 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.97M.
  • Madrigal Pharmaceuticals made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #668 holding.
  • Geode Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Geode Capital Management's Madrigal Pharmaceuticals position peaked at $263M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.